Convidecia (Adenovirus Type 5 Vector) / CanSino, NPO Petrovax - LARVOL DELTA

Single-Cell Sequencing Reveals Varying Cell-Mediated Immunity Profiles in Individuals with Distinct Antibody Responses Following Ad5-nCoV Booster. (PubMed, J Infect Dis) - "These findings elucidate the cellular and molecular mechanisms underlying robust immune responses to the Ad5-nCoV booster, highlighting the critical role of cellular immunity. By integrating humoral and cellular insights, this study offers a new perspective of comprehensive framework for evaluating vaccine efficacy."

Journal • Infectious Disease • CD8

Modeling of antibody waning after heterologous boosting with Ad5-nCoV in individuals primed with two-dose CoronaVac previously. (PubMed, Hum Vaccin Immunother) - P1/2, P4 | "For the Omicron BA.1 variant, the half-life was 314 d (248-453) in the aerosolized Ad5-nCoV group, 168 d (159-180) in the intramuscular Ad5-nCoV group, compared to 196 d (174-230) in the three-dose CoronaVac group. Our model indicated that the heterologous booster with Ad5-nCoV after two-dose CoronaVac, particularly the aerosolized Ad5-nCoV, induces longer-lasting neutralizing antibodies than three-dose CoronaVac, preferably characterized by power-law decay models."

Clinical • Journal

Short-Term Change in IgG Antibody Elicited by Omicron BA.5 Infection and Inhaled Ad5-nCoV Vaccine Among Healthcare Workers. (PubMed, Immun Inflamm Dis) - "These findings suggested that the inhaled adenovirus vector vaccine may provide modest protection against Omicron BA.5 infection in the healthcare worker population."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Ad5-boosted COVID-19 vaccine reduces symptomatic BA.5 infection via cross-neutralizing antibodies and NK cell immunity. (PubMed, BMC Med) - "Ad5-nCoV booster vaccination confers enhanced protection against symptomatic BA.5 infection through cross-reactive NAbs with expanded epitope breadth and NK cell-mediated innate immunity enhancement. This retrospective study provides insights into the immunogenicity and molecular mechanisms of two vaccination strategies against real-world BA.5 infection, highlighting Ad5-based technology's efficacy. It provides guidance for future vaccination strategies against emerging Disease X, emphasizing the value of retrospective real-world analyses in vaccine development."

Journal • Retrospective data • Infectious Disease • Novel Coronavirus Disease

Gut-initiated mucosal and systemic immunity against SARS-CoV-2 via an oral hyaluronic acid/chitosan vaccine coacervate. (PubMed, J Control Release) - "Importantly, TC/HA coacervates similarly enhanced protein antigen immunogenicity, inducting robust humoral and mucosal immunity. Therefore, we established the THT coacervate as a highly promising and widely applicable oral platform to generate protective systemic and mucosal immunity against respiratory viral infections."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Neutralization and Anti-S Antibody Titers in SARS-CoV-2 Boosted Adults in Mexico: A Comparison Across Five Vaccine Types. (PubMed, Int J Microbiol) - "We observed that the highest anti-protein S GMTs were in the group that received a heterologous booster with BNT162b2, AZD1222, Ad5-nCoV, or CoronaVac; the group without a booster showed the lowest GMTs...Boosters increased GMTs for all people, independently of their primary vaccine scheme. Yet, our findings suggest that a heterologous booster produced higher titers against SARS-CoV-2 protein S. Efforts should be made to reach people who received AZD1222 and Ad5-nCoV as their primary scheme and did not get boosted, as neutralization in those groups was particularly low."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • PROS1

Impact of an aerosolized or intramuscular adenovirus type 5-vectored COVID-19 vaccine on Fc-mediated immune effector functions in a hybrid immunity population. (PubMed, Front Immunol) - "Intramuscular Ad5-nCoV vaccination elicited robust ADCP, ADNP, and ADCC responses, while the aerosolized formulation primarily induced ADCC activity. Fc-mediated effector functions exhibited greater cross-reactivity against emerging variants compared to neutralizing antibodies, but correlated only weakly with neutralizing antibody titers."

Clinical • Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Kinetics of IgA Subtypes and Cytokines in Respiratory Secretions Following Immunization With COVID-19 Mucosal Vaccine. (PubMed, J Med Virol) - "This is a study to demonstrate compartmentalized IgA subclass dynamics between upper (nasal) and lower (sputum) respiratory tracts following mucosal vaccination. Our findings highlight the need for optimized mucosal vaccine formulations to enhance respiratory immunity, providing critical insights for developing next-generation COVID-19 vaccines targeting the complex mucosal immune microenvironment."

Journal • Infectious Disease • Influenza • Novel Coronavirus Disease • Respiratory Diseases • IL6

Safety and Immunogenicity of aerosolized adenovirus-vectored COVID-19 vaccine and intramuscular mRNA vaccine bivalent boosters: a randomized open-label clinical trial. (PubMed, Nat Commun) - P=N/A | "This trial met the main hypothesis; the findings may provide insights for the development of the next-generation COVID-19 vaccines. Clinical Trials.gov identifier: NCT05886790."

Clinical • Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • CXCR3

Phase IIb Trial of Recombinant Novel Coronavirus Vaccine (Ad5-nCoV) in Adults 18 Years of Age and Older, Living With HIV (clinicaltrials.gov) - P2 | N=155 | Completed | Sponsor: Fundación Huésped | Recruiting ➔ Completed | Phase classification: P2b ➔ P2 | N=876 ➔ 155

Enrollment change • Phase classification • Trial completion • Human Immunodeficiency Virus • Infectious Disease • Novel Coronavirus Disease • CD4

FH-63: Phase IIB Study of Recombinant Novel Coronavirus Vaccine (clinicaltrials.gov) - P2 | N=88 | Completed | Sponsor: Fundación Huésped | Active, not recruiting ➔ Completed | Phase classification: P2b ➔ P2 | N=450 ➔ 88

Enrollment change • Phase classification • Trial completion • Infectious Disease • Novel Coronavirus Disease

Immune response induced by the recombinant novel coronavirus vaccine (Adenovirus type 5 vector) (Ad5-nCoV) in persons living with HIV (PLWH). (PubMed, PLoS One) - P2b | "The Ad5-nCoV vaccine was safe and induced an adequate immune response in virologically suppressed PLWH, maintaining high antibody titers at least during the first year post-vaccination. No significant changes were observed in plasma viral load, CD4 count and CD4/CD8 ratio."

Journal • Human Immunodeficiency Virus • Infectious Disease • Novel Coronavirus Disease • Pain • Respiratory Diseases • CD4 • CD8

A review of currently licensed mucosal COVID-19 vaccines. (PubMed, Vaccine) - "This highlights the importance of expanded research in this field. In this review, we aim to summarize what is known about these currently licensed vaccines, with an emphasis on the key findings obtained in both preclinical and clinical studies."

Journal • Review • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Cryo-ET unravels the mystery of Ad5-nCoV vaccines. (PubMed, Structure) - "However, the molecular mechanisms underlying its high immunogenicity and potential adverse reactions have remained elusive. In this issue of Structure, Dong et al.1 employed cryo-electron tomography as a powerful technique to show that abundant prefusion spike protein formation is induced by Ad5-nCoV vaccines."

Journal • Infectious Disease • Novel Coronavirus Disease

Pooled Analysis of the Effect of Pre-Existing Ad5 Neutralizing Antibodies on the Immunogenicity of Adenovirus Type 5 Vector-Based COVID-19 Vaccine from Eight Clinical Trials. (PubMed, Vaccines (Basel)) - " Regardless of whether Ad5-nCoV is administered as a primary vaccination regimen or as a heterologous prime-boost strategy, a negative impact on immunogenicity can still be observed in the presence of high pre-existing immunity. However, when primary immunization is achieved with inactivated COVID-19 vaccines, aerosol inhalation can significantly enhance the immunogenicity of Ad5-nCoV compared to intramuscular injections of Ad5-nCoV as a booster."

Journal • Retrospective data • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Boosting with Omicron-specific mRNA vaccine or historical SARS-CoV-2 vaccines elicits discriminating immune responses against Omicron variants. (PubMed, Acta Pharm Sin B) - "Moreover, the protective efficacies of the vaccines in booster vaccinations are highly related to GC reactions in secondary lymphatic organs. In summary, these findings provide timely important information on prime-boost regimens and future vaccine design."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Effectiveness of a booster dose of aerosolized or intramuscular adenovirus type 5 vectored COVID-19 vaccine in adults: a multicenter, partially randomized, platform trial in China. (PubMed, Nat Commun) - P4 | "From 14 days after the vaccination, 14 (15/1000 person-years), 19 (20/1000 person-years), and 34 (37/1000 person-years) COVID-19 cases were confirmed in the IH Ad5-nCoV group, the IM Ad5-nCoV group, and the control group, respectively, which resulted in an adjusted effectiveness of 52.3% (95% CI 10.4 to 74.6) for IH Ad5-nCoV and 37.2% (95% CI -11.2 to 64.5) for IM Ad5-nCoV. The IH Ad5-nCoV booster was associated with a lower incidence of symptomatic COVID-19, but there is no solid evidence that IH Ad5-nCoV was more effective than IM Ad5-nCoV."

Clinical • Journal • Infectious Disease • Novel Coronavirus Disease

Molecular basis of Ad5-nCoV vaccine-induced immunogenicity. (PubMed, Structure) - "Ad5-nCoV_O induced S proteins exhibit improved stability and reduced syncytia formation among inoculated cells. Our work demonstrates that Ad5-nCoV is a prominent platform for antigen induction and cryo-ET can be a useful technique for vaccine characterization and development."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Comparative efficacy of leading COVID-19 vaccines: A network meta-analysis. (PubMed, Indian J Med Res) - "The statistically significant direct estimates were obtained by Spikevax [VE: 93.29 (91.31, 95.27); P<0.05], Pfizer BioNTech [VE: 92.07 (90.03, 94.12); P<0.05], Sputnik [VE: 91.60 (85.60, 97.60); P<0.05], Novavax [VE: 88.99 (83.55, 94.42); P<0.05], Sinovac [VE: 83.50 (65.40, 101.60); P<0.05], Covifenz [VE: 77.27 (68.48, 86.06); P<0.05], Zifivax [VE: 75.94 (70.86, 81.02); P<0.05], Covishield [VE: 72.34 (67.12, 77.56); P<0.05], S-Trimer [VE: 71.61 (56.23, 86.98); P<0.05], Covaxin [VE: 70.81 (65.33, 76.29); P<0.05], Soberna [VE: 69.70 (56.50, 82.90); P<0.05], Zydus Cadila [VE: 66.60 (47.60, 85.60); P<0.05], CVnCoV [VE: 63.70 (52.20, 75.20); P<0.05], Convidecia [VE: 57.50 (39.70, 75.30); P <0.05], and Jcovden [VE : 52.42 (47.28, 57.57); P<0.05]. Spikevax emerged triumphant with an unparalleled P score of 0.95, solidifying its status as a top ranking prevention tool against the COVID-19 in our investigation. Our analysis reveals a..."

Clinical • Journal • Retrospective data • Review • Infectious Disease • Novel Coronavirus Disease

Safety and immunogenicity of Ad5-nCoV administered intradermally by needle-free injector in rats. (PubMed, Front Med (Lausanne)) - "Comparable levels of neutralizing antibodies against various variants induced by NFI compared to NI at the same dosage. The NFI immunization would be considered as an alternative immunization method to replace the traditional NI for the Ad5-nCoV."

Journal • Preclinical • Infectious Disease • Novel Coronavirus Disease

Comparison of Phenotypes of Headaches After COVID-19 Vaccinations Differentiated According to the Vaccine Used. (PubMed, Vaccines (Basel)) - "Compared with the Comirnaty, Covilo, and Vaxzevria vaccines, the Spikevax vaccine induced significantly greater headache intensities...This knowledge is clinically relevant in differentiating life-threatening vaccination complications, such as thrombotic syndromes, which are also associated with headaches. Based on these results, new diagnostic criteria for postvaccinal headaches can be developed."

Journal • Infectious Disease • Novel Coronavirus Disease • Pain • Respiratory Diseases

Heterologous Prime-boost Immunization with an Aerosolised Adenovirus Type-5 Vector-based COVID-19 Vaccine (Ad5-nCoV) After Priming with an Inactivated SARS-CoV-2 Vaccine (clinicaltrials.gov) - P1/2 | N=423 | Completed | Sponsor: Jiangsu Province Centers for Disease Control and Prevention | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Heterologous Boost Immunization with Ad5-nCoV After Three-dose Priming with an Inactivated SARS-CoV-2 Vaccine (clinicaltrials.gov) - P4 | N=362 | Completed | Sponsor: Jiangsu Province Centers for Disease Control and Prevention | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • IFNG • IL2 • TNFA

Heterologous Boost Immunization with an Aerosolised Ad5-nCoV After Two-dose Priming with an Inactivated SARS-CoV-2 Vaccine (clinicaltrials.gov) - P3 | N=10285 | Completed | Sponsor: Jiangsu Province Centers for Disease Control and Prevention | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Waning neutralizing antibodies through 180 days after homologous and heterologous boosters of inactivated COVID-19 vaccine. (PubMed, Front Public Health) - "In summary, neutralizing antibody levels significantly waned 180 days after the third vaccine dose, with the most pronounced decline occurring within the initial 90 days. Heterologous boosting with Convidecia demonstrated a more robust, durable, and broad humoral immune response compared to boosting with inactivated vaccines or Zifivax, suggesting that adenovirus vector vaccines possess a special advantage in the realm of vaccine development for preventing infectious diseases."

Clinical • Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases